JP2013544600A - 固体デリバリーのための治療方法および組成物 - Google Patents

固体デリバリーのための治療方法および組成物 Download PDF

Info

Publication number
JP2013544600A
JP2013544600A JP2013541061A JP2013541061A JP2013544600A JP 2013544600 A JP2013544600 A JP 2013544600A JP 2013541061 A JP2013541061 A JP 2013541061A JP 2013541061 A JP2013541061 A JP 2013541061A JP 2013544600 A JP2013544600 A JP 2013544600A
Authority
JP
Japan
Prior art keywords
tissue
drug
administration device
reporter
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013541061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544600A5 (enExample
Inventor
クリングホッファー，リチャード
フラジエ，ジェイソン
グレンリー，マーク
Original Assignee
プレサージュ バイオサイエンシズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレサージュ バイオサイエンシズ，インコーポレイテッド filed Critical プレサージュ バイオサイエンシズ，インコーポレイテッド
Publication of JP2013544600A publication Critical patent/JP2013544600A/ja
Publication of JP2013544600A5 publication Critical patent/JP2013544600A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/1407—Infusion of two or more substances
    • A61M5/1408—Infusion of two or more substances in parallel, e.g. by manifolds or with sequencing valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14212—Pumping with an aspiration and an expulsion action
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
    • A61M5/3298—Needles arranged in parallel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
JP2013541061A 2010-11-23 2011-11-23 固体デリバリーのための治療方法および組成物 Pending JP2013544600A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US41668610P 2010-11-23 2010-11-23
US61/416,686 2010-11-23
US41715710P 2010-11-24 2010-11-24
US61/417,157 2010-11-24
US201161454115P 2011-03-18 2011-03-18
US61/454,115 2011-03-18
US201161475594P 2011-04-14 2011-04-14
US61/475,594 2011-04-14
US201161475858P 2011-04-15 2011-04-15
US61/475,858 2011-04-15
US201161483437P 2011-05-06 2011-05-06
US61/483,437 2011-05-06
PCT/US2011/062128 WO2012071559A2 (en) 2010-11-23 2011-11-23 Therapeutic methods and compositions for solid delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017003763A Division JP2017109112A (ja) 2010-11-23 2017-01-13 固体デリバリーのための治療方法および組成物

Publications (2)

Publication Number Publication Date
JP2013544600A true JP2013544600A (ja) 2013-12-19
JP2013544600A5 JP2013544600A5 (enExample) 2015-01-22

Family

ID=46146433

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013541061A Pending JP2013544600A (ja) 2010-11-23 2011-11-23 固体デリバリーのための治療方法および組成物
JP2017003763A Pending JP2017109112A (ja) 2010-11-23 2017-01-13 固体デリバリーのための治療方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017003763A Pending JP2017109112A (ja) 2010-11-23 2017-01-13 固体デリバリーのための治療方法および組成物

Country Status (7)

Country Link
US (4) US20140114279A1 (enExample)
EP (2) EP2643045A4 (enExample)
JP (2) JP2013544600A (enExample)
CN (2) CN108744262A (enExample)
AU (1) AU2011332815A1 (enExample)
CA (1) CA2816883A1 (enExample)
WO (1) WO2012071559A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210022737A (ko) 2018-07-09 2021-03-03 각고호우징 게이오기주크 주입 기구 세트
JP2022506515A (ja) * 2018-11-05 2022-01-17 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 制御性ｒｎａを発現させるためのベクターシステム
US12410446B2 (en) 2016-01-15 2025-09-09 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US12709753B2 (en) 2018-01-09 2026-08-18 American Gene Technologies International Inc. HIV immunotherapy with no pre-immunization step

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035598T2 (en) 2008-12-02 2018-05-28 Allergan Inc Injection device
CA2689400C (en) * 2009-12-30 2023-01-10 Kenneth W. Adams Therapeutic agent delivery apparatus and process
CN104023760A (zh) 2011-10-28 2014-09-03 普莱萨格生命科学公司 药物递送方法
CA2880704A1 (en) * 2012-08-08 2014-02-13 Presage Biosciences, Inc. Extrusion methods and devices for drug delivery
CA2899994C (en) * 2013-02-25 2022-08-30 Imabiotech Method to evaluate the tissue targeting of a molecule of interest
US20140350518A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Syringe extrusion accessory
US20140350516A1 (en) 2013-05-23 2014-11-27 Allergan, Inc. Mechanical syringe accessory
US10029048B2 (en) 2014-05-13 2018-07-24 Allergan, Inc. High force injection devices
RU2602452C2 (ru) * 2014-05-14 2016-11-20 Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук Способ выявления веществ и их композиций с противоопухолевой активностью
US20160058889A1 (en) * 2014-08-11 2016-03-03 The Board Of Regents Of The University Of Texas System Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
GB201414464D0 (en) 2014-08-14 2014-10-01 Technion Res & Dev Foundation Compositions and methods for therapeutics prescreening
KR101636775B1 (ko) * 2014-08-19 2016-07-08 아주대학교산학협력단 부위마취 장치 및 방법
US10226585B2 (en) 2014-10-01 2019-03-12 Allergan, Inc. Devices for injection and dosing
CN104483321B (zh) * 2014-10-31 2017-07-28 苏州捷碧医疗科技有限公司 一种基于机器视觉的注射针管自动检测系统和检测方法
WO2016101069A1 (en) * 2014-12-23 2016-06-30 Atkinson Cole Michael Joseph Multiple needle assembly
KR20170136522A (ko) 2015-03-10 2017-12-11 알러간 파마슈티컬스 홀딩스 (아일랜드) 언리미티드 컴파니 다중 바늘 주입기
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
CN105671082B (zh) * 2016-01-18 2020-08-07 武汉淼灵生物科技有限公司 一种表达外泌体标记物的慢病毒载体及其构建方法和应用
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
KR102288170B1 (ko) 2016-04-08 2021-08-09 알레간 인코포레이티드 흡인 및 주입 디바이스
USD867582S1 (en) 2017-03-24 2019-11-19 Allergan, Inc. Syringe device
US12559769B2 (en) 2017-06-16 2026-02-24 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
US10668247B2 (en) * 2017-11-15 2020-06-02 Alcyone Lifesciences, Inc. Therapy specific, pre-programmed auto injection device
JP7653164B2 (ja) * 2019-09-27 2025-03-28 バージニア コモンウェルス ユニバーシティー 組織を修復または増加させるための組成物および方法
CN114761054B (zh) * 2019-10-22 2025-07-15 佐治亚科技研究公司 利用浇铸制剂中的组分溶解度的调整来制作微针的方法
NL2024277B1 (en) * 2019-11-21 2021-08-11 Imcomet B V Interstitial fluid removal device
USD933205S1 (en) * 2020-02-28 2021-10-12 Jeisys Medical Inc. Needle array
CN112452365B (zh) * 2020-11-23 2021-12-07 无锡市夸克微智造科技有限责任公司 微加工流体装置
WO2022175545A1 (en) * 2021-02-22 2022-08-25 Dinaqor Ag Loco-regional perfusion of a liver
BR112023016797A2 (pt) * 2021-02-22 2024-01-16 Dinaqor Ag Perfusão loco-regional de um rim
US11938087B2 (en) * 2021-08-23 2024-03-26 Young Hei Lee Intramuscular stimulation needling device
GB2612576B (en) * 2021-10-28 2025-02-26 Active Needle Tech Ltd Injection device
CN114569798B (zh) * 2022-02-22 2023-03-28 湖南华耀百奥医疗科技有限公司 一种多孔植入物及其制备方法和应用
CN115321499B (zh) * 2022-08-11 2023-10-13 哈尔滨理工大学 一种用于生物成像的黑磷纳米片复合材料的制备
US20250064336A1 (en) * 2023-08-24 2025-02-27 Johnson & Johnson Enterprise Innovation Inc. Tissue classification system for detecting cancerous cells
WO2025054607A1 (en) * 2023-09-07 2025-03-13 The Regents Of The University Of California Compositions and methods for treating sarcopenia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022252A2 (en) * 2008-08-21 2010-02-25 Third Rock Ventures Device and method for drug evaluation and local treatment

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US5242794A (en) 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
ATE81724T1 (de) 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
US5030002A (en) 1989-08-11 1991-07-09 Becton, Dickinson And Company Method and apparatus for sorting particles with a moving catcher tube
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
IE76732B1 (en) 1990-08-07 1997-11-05 Becton Dickinson Co One step test for absolute counts
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0592626B1 (en) 1992-03-11 2003-01-29 Dana-Farber Cancer Institute, Inc. METHODS TO CLONE mRNA
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
DE69433922T2 (de) 1993-11-09 2005-07-28 Medical College Of Ohio, Toledo Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US8795242B2 (en) * 1994-05-13 2014-08-05 Kensey Nash Corporation Resorbable polymeric device for localized drug delivery
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
US5751629A (en) 1995-04-25 1998-05-12 Irori Remotely programmable matrices with memories
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびａａｖの精製
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたａａｖベクター
CA2187969C (en) 1995-10-17 2006-05-30 Dale L. Boger A template for solution phase synthesis of combinatorial libraries
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5935788A (en) 1996-06-25 1999-08-10 Lifespan Biosciences, Inc. Subtractive hybridization techniques for identifying differentially expressed and commonly expressed nucleic acid
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
US5798035A (en) 1996-10-03 1998-08-25 Pharmacopeia, Inc. High throughput solid phase chemical synthesis utilizing thin cylindrical reaction vessels useable for biological assay
AU8921698A (en) 1997-08-29 1999-03-16 Human Genome Sciences, Inc. Follistatin-3
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999018981A1 (en) * 1997-10-10 1999-04-22 The Regents Of The University Of California Implants comprising combinations of allogeneic cells for use in cancer treatment
US5942420A (en) 1997-11-17 1999-08-24 Millennium Biotherapeutics, Inc. Molecules of the follistatin-related protein family and uses therefor
US6129670A (en) * 1997-11-24 2000-10-10 Burdette Medical Systems Real time brachytherapy spatial registration and visualization system
US20030022207A1 (en) 1998-10-16 2003-01-30 Solexa, Ltd. Arrayed polynucleotides and their use in genome analysis
US6410013B1 (en) * 1999-01-25 2002-06-25 Musc Foundation For Research Development Viral vectors for use in monitoring HIV drug resistance
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US6689103B1 (en) * 1999-05-07 2004-02-10 Scimed Life System, Inc. Injection array apparatus and method
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US6582938B1 (en) 2001-05-11 2003-06-24 Affymetrix, Inc. Amplification of nucleic acids
US6450937B1 (en) * 1999-12-17 2002-09-17 C. R. Bard, Inc. Needle for implanting brachytherapy seeds
US6558361B1 (en) * 2000-03-09 2003-05-06 Nanopass Ltd. Systems and methods for the transport of fluids through a biological barrier and production techniques for such systems
US6478776B1 (en) * 2000-04-05 2002-11-12 Biocardia, Inc. Implant delivery catheter system and methods for its use
US7850663B2 (en) * 2001-01-12 2010-12-14 Becton, Dickinson And Company Medicament microdevice delivery system, cartridge and method of use
JP4383168B2 (ja) * 2001-09-12 2009-12-16 ベクトン・ディキンソン・アンド・カンパニー マイクロ針投与デバイスおよび薬物投与デバイス
AU2003286911A1 (en) * 2002-11-04 2004-06-07 Dana-Farber Cancer Institute, Inc. In vivo imaging of e2f-regulated bioluminescent proteins
US6896666B2 (en) * 2002-11-08 2005-05-24 Kochamba Family Trust Cutaneous injection delivery under suction
WO2004078984A1 (en) * 2003-03-05 2004-09-16 Janssen Pharmaceutica N.V. Animal model for the fast identification of pharmaceutical active compounds in vivo
US20050137525A1 (en) * 2003-06-04 2005-06-23 Georgia Tech Research Corporation Drilling microneedle device
CA2530531A1 (en) * 2003-06-30 2005-01-20 Alza Corporation Formulations for coated microprojections containing non-volatile counterions
US7097631B2 (en) * 2003-10-31 2006-08-29 Alza Corporation Self-actuating applicator for microprojection array
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
US20060024711A1 (en) 2004-07-02 2006-02-02 Helicos Biosciences Corporation Methods for nucleic acid amplification and sequence determination
US20060024678A1 (en) 2004-07-28 2006-02-02 Helicos Biosciences Corporation Use of single-stranded nucleic acid binding proteins in sequencing
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
WO2006128034A1 (en) * 2005-05-25 2006-11-30 Georgia Tech Research Corporation Microneedles and methods for microinfusion
US20070093748A1 (en) * 2005-06-23 2007-04-26 Medtronic Vascular, Inc. Methods and systems for treating injured cardiac tissue
US20070038181A1 (en) * 2005-08-09 2007-02-15 Alexander Melamud Method, system and device for delivering a substance to tissue
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20070162110A1 (en) * 2006-01-06 2007-07-12 Vipul Bhupendra Dave Bioabsorbable drug delivery devices
US7771741B2 (en) 2006-05-01 2010-08-10 Warsaw Orthopedic, Inc Demineralized bone matrix devices
US20070283453A1 (en) * 2006-05-31 2007-12-06 Juan Carlos Rodriguez Cimadevilla Animal models of tumor metastasis and toxicity
BRPI0602640B8 (pt) * 2006-07-06 2021-05-25 Anhanguera Educacional Ltda métodos de obtenção de penta-1,4-dien-3-onas e de cicloexanonas substituídas e derivados com propriedades antitumorais e antiparasitárias, processo para preparar 1,5-bis-(aril)-penta-1,4-dien-3-onas alquiladas e aciladas, processo para preparar 4-nitro-3,5-diaril-cicloexanonas substituídas, processo para preparar 2,6-dibenzilideno-4-nitro-3,5-diaril-cicloexanonas substituídas, processo para preparar uma mistura formada por quantidades determinadas dos compostos (1,5-bis(4-hidróxi-3-metóxi-fenil)penta-1,4-dien-3-ona) e (1,5-bis(3-metóxi-4-acetóxi-fenil)penta-1,4-dien-3-ona), compostos e seus usos, composição farmacêutica, método terapêutico para tratamento dos cânceres e composição sinérgica
EP2056902A1 (en) * 2006-08-21 2009-05-13 Koninklijke Philips Electronics N.V. Drug delivery device with piezoelectric actuator
JP2010502268A (ja) * 2006-08-29 2010-01-28 ナノメド ディヴァイシーズ， インコーポレイテッド 活性物質の経皮送達及びサンプリングのための高アスペクト比マイクロデバイス及びその方法
US20080140026A1 (en) * 2006-12-11 2008-06-12 Sliwa John W Acoustically-Aided and/or gel-aided delivery of beneficial gaseous, ionic, unstable, metastable, short-lived or reactive species for medical purposes
WO2008079997A2 (en) * 2006-12-22 2008-07-03 Medtronic, Inc. Implantable device, angiogenesis mechanism and methods
US20080214987A1 (en) * 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
EP2404628B1 (en) * 2007-07-06 2014-09-24 Boston Scientific Scimed, Inc. Implantable medical devices having adjustable pore volume and methods for making the same
JP5588344B2 (ja) * 2007-08-14 2014-09-10 フレッド ハッチンソン キャンサー リサーチ センター 治療薬をデリバリーするための針アレイアセンブリ及び方法
US20090093871A1 (en) * 2007-10-08 2009-04-09 Medtronic Vascular, Inc. Medical Implant With Internal Drug Delivery System
WO2010064251A1 (en) * 2008-12-04 2010-06-10 Technion Research & Development Foundation Ltd Hydrogel sponges, methods of producing them and uses thereof
US9408542B1 (en) 2010-07-22 2016-08-09 Masimo Corporation Non-invasive blood pressure measurement system
TWI497333B (zh) 2011-06-14 2015-08-21 Giant Mfg Co Ltd 自行車適配產生方法、自行車適配系統與電腦程式產品
US9104666B2 (en) 2012-09-04 2015-08-11 Oracle International Corporation Controlling access to a large number of electronic resources

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022252A2 (en) * 2008-08-21 2010-02-25 Third Rock Ventures Device and method for drug evaluation and local treatment

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410446B2 (en) 2016-01-15 2025-09-09 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US12709753B2 (en) 2018-01-09 2026-08-18 American Gene Technologies International Inc. HIV immunotherapy with no pre-immunization step
KR20210022737A (ko) 2018-07-09 2021-03-03 각고호우징 게이오기주크 주입 기구 세트
JP2022506515A (ja) * 2018-11-05 2022-01-17 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド 制御性ｒｎａを発現させるためのベクターシステム

Also Published As

Publication number Publication date
EP2767298A3 (en) 2014-10-01
US20140114279A1 (en) 2014-04-24
CN103492016A (zh) 2014-01-01
EP2643045A2 (en) 2013-10-02
US20210170052A1 (en) 2021-06-10
CA2816883A1 (en) 2012-05-31
CN108744262A (zh) 2018-11-06
US20180256754A1 (en) 2018-09-13
WO2012071559A3 (en) 2012-07-26
AU2011332815A1 (en) 2013-05-30
US20140170072A1 (en) 2014-06-19
EP2767298A2 (en) 2014-08-20
JP2017109112A (ja) 2017-06-22
WO2012071559A2 (en) 2012-05-31
EP2643045A4 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
US20210170052A1 (en) Therapeutic methods and compositions for solid delivery
Roy et al. Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid β plaques
Xie et al. Astrocyte-neuron crosstalk through Hedgehog signaling mediates cortical synapse development
Babaeijandaghi et al. Metabolic reprogramming of skeletal muscle by resident macrophages points to CSF1R inhibitors as muscular dystrophy therapeutics
Debattisti et al. Dysregulation of mitochondrial Ca2+ uptake and sarcolemma repair underlie muscle weakness and wasting in patients and mice lacking MICU1
US20130280755A1 (en) Therapeutic methods for solid delivery
Girolamo et al. Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice
Cui et al. Targeted expression of μ-opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward
Echigoya et al. Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy
Zhou et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice
Kastenschmidt et al. A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression
Wiltgen et al. The hippocampus plays a selective role in the retrieval of detailed contextual memories
Novak et al. Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
US8173376B2 (en) Method for identifying compounds for treatment of pain
AU2014221659B2 (en) Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to injury
Ki et al. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors
Deng et al. A novel brain-permeant chemotherapeutic agent for the treatment of brain metastasis in triple-negative breast cancer
Nagaoka et al. Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist–induced orofacial dyskinesia
Boyle et al. The ventral CA2 region of the hippocampus and its differential contributions to social memory and social aggression
King et al. Polymer scaffolds delineate healthy from diseased states at sites distal from the pancreas in two models of type 1 diabetes
Joppé et al. Genetic targeting of neurogenic precursors in the adult forebrain ventricular epithelium
Nijhuis et al. Developing a minimally invasive gene therapy for multiple sclerosis
Veluthakal et al. In vivo beta-cell imaging with VMAT 2 Ligands-current state-of-the-art and future perspectives
Stitelman et al. Robust in vivo transduction of nervous system and neural stem cells by early gestational intra amniotic gene transfer using lentiviral vector
Evans et al. Tet2-mediated clonal hematopoiesis modestly improves neurological deficits and is associated with inflammation resolution in the subacute phase of experimental stroke

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151013

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151016

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160913